Condition: Metastatic Colorectal Cancer · Prostate Cancer Metastatic · Prostate Cancer Locally Advanced · Sponsor: CuraCell TX AB
This is a First-In-Human trial investigating a novel expansion protocol of an ATIMP (CC-38), composed of autologous TIL.
This description comes directly from the study's public registry record.
Dragan Kiselicki, Dr. · 0069 7601 4420 · probetility@ikf-khnw.de
Sabine Beck, Dr. · 0069 7601 4420 · probetility@ikf-khnw.de
Always discuss trial participation with your own doctor first.
| Krankenhaus Nordwest | Frankfurt, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07255664